1 Corporate Presentation July 2014

2 The presentation may contain “forward - looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Reference is made in particular to the description of our plans and objectives for future operations, assumptions underlying such plans and objectives and other forward - looking terminology such as “may,” “expects,” “believes,” “anticipates,” “intends,” “projects,” or similar terms, variations of such terms or the negative of such terms. Forward - looking statements are based on management’s current expectations. Actual results could differ materially from those currently anticipated and such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to availability of financing, difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product development or commercialization and the uncertainty of patent protection for the Company's intellectual property or trade secrets. Safe Harbor

3 Titan Pharmaceuticals Overview Titan Pharmaceuticals is a specialty pharmaceutical company focused on developing innovative treatments for chronic conditions based on its proprietary long - term drug delivery platform, ProNeura ™ • Probuphine ® : A long acting formulation of buprenorphine for the maintenance treatment of opioid dependence • Final Phase 3 clinical study requested by the FDA in progress; expected completion by mid year 2015 and resubmission of the NDA in late 2015 • Partnership established for the U.S. and Canadian rights on attractive terms • Potential application in treatment of chronic pain • ProNeura for Parkinson’s disease ( Ropinirole ) • Non clinical proof - of - principle study completed in primate model of PD • Expect to file Investigational New Drug application with FDA in 2015 • ProNeura Technology Platform • Proprietary long - term drug delivery technology providing around - the - clock medication over periods of six months to a year • Applications in chronic conditions where clinical benefit could be achieved by continuous, stable medication levels in the blood

4 Probuphine : Highlights Probuphine is expected to be the first long acting buprenorphine product on the market for the treatment of opioid dependence • Probuphine provides six month sustained release of buprenorphine, a drug already on the market as a daily dosed sublingual tablet/film • Expanding market with U.S. sales of daily dosed buprenorphine products exceeding $1.5 billion; Probuphine peak sales potential: $300 - $500 mil • Strong U.S. and Canadian partnership with Braeburn Pharmaceuticals • Upfront : $15.75 mil; Approval: $15 mil; Sales Milestones: $165 mil; • Tiered royalties: mid teens – low twenties • U.S. patent life to 2024 • Potential application in treating chronic pain • Regulatory status: • NDA accepted for Priority Review in January 2013 and FDA Advisory Committee voted in favor of approval of Probuphine in March 2013 • FDA issued a Complete Response Letter (CRL) on April 30, 2013 requesting additional clinical testing • Final clinical study in progress and resubmission of NDA expected in late 2015

5 Recognized as an epidemic by the federal government • Opioid dependence is recognized by the government as a medical epidemic that warrants immediate and significant resource allocation • NIDA (part of NIH) provided a $7.6 million grant (2010 - 2011) in support of Probuphine development Sources: EPIDEMIC: RESPONDING TO AMERICA’S PRESCRIPTION DRUG ABUSE CRISIS, Executive Office of the President of the United St ate s (2011); 2009 National Survey on Drug Use and Health (NSDUH); “A Wave of Addiction and Crime, with the Medicine Cabinet to Blame”, New York Ti mes (Sept 23, 2010) ER Visits Due to Opioid Misuse 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 2004 2005 2006 2007 2008 2009 MM of Patient Visits 240% increase in 6 years Opioid Dependence - Viewed as an Epidemic

6 • Addiction is a primary, chronic disease of brain reward, motivation, memory and related neurobiological circuitry* • Inability to consistently abstain • Impairment in behavioral control • Craving • Diminished recognition of significant problems with one’s behaviors • Addiction involves cycles of relapse and remission • Without treatment or engagement in recovery activities, addiction is progressive and can result in disability or premature death * American Society of Addiction Medicine, Inc., 2011 Opioid Dependence - Disease Overview

7 • In the U.S. buprenorphine has replaced methadone as the gold standard in treating opioid dependence • Buprenorphine is a mixed partial agonist at the mu receptor and an antagonist at the kappa receptor • Ceiling effect • Improved safety profile • Lack of euphoria Ceiling Effect of Buprenorphine Opioid Dependence - Treatment Overview

8 • Daily buprenorphine is the current gold standard • U.S. sales of daily oral formulations of buprenorphine ( Suboxone ®) exceeded $1.4B in 2012 • U.S. buprenorphine prescriptions have far outstripped those of methadone since 2006 • Challenges with oral buprenorphine • Compliance • Fluctuating levels of drug • Diversion, abuse Source: IMS Health Opioid Dependence - Expanding Market 0 200 400 600 800 1000 1200 1400 1600 2008 2009 2010 2011 2012 Suboxone Brand Gross Sales 2008 - 2012

9 EVA polymer Buprenorphine Blended & Extruded 26 mm long, 2.5 mm diameter Each implant contains 80 mg of buprenorphine HCl which has been blended and extruded with ethylene vinyl acetate (EVA) co - polymer Probuphine is a subdermal implant capable of delivering continuous and persistent around the clock blood levels of buprenorphine for 6 months following a single treatment, enhancing patient compliance and retention Inert component of several approved products Approved for treatment of opioid addiction, and acute and chronic pain Probuphine Probuphine : Active Buprenorphine Along with Inert EVA Polymer

10 • Six clinical studies completed to date with final Phase 3 study under way • Small dose finding study • Two well - controlled safety and efficacy studies showing clinical and statistical superiority over placebo and non - inferiority to Suboxone published in Journal of American Medical Association and in the journal Addiction • Two open label long - term treatment safety studies • Relative bioavailability study • Mild - to - moderate adverse events typical of the safety profile of buprenorphine; low number of serious adverse events similar to placebo • Well - tolerated implant procedure • No evidence of implant diversion or misuse Probuphine Clinical Summary

11 Pro - 814 Study Design: Follow - up 24 Weeks (Weeks 1 to 24) Monthly Visits Group A : Daily SL BPN ≤ 8 mg 4 placebo implants Screening R Clinically stable, Daily ≤ 8 mg SL BPN for at least 90 days, Opioid - negative urine toxicology for last 90 days Maintenance Phase 2 Weeks (25 to 26) Up to 2 Weeks (Weeks - 2 to - 1) 24 Weeks (6 months) on Treatment SL BPN = sublingual buprenorphine or sublingual buprenorphine/naloxone 6 Scheduled Urine Toxicology & Other Study Assessments (one per month) 4 Random Urine Toxicology R Randomization takes place on Day 1 (day of implant) Group B : 4 Probuphine implants Daily SL placebo The final clinical study is a randomized, double blind and double dummy design that will provide information for a non - inferiority comparison of a six - month treatment with a dose of four Probuphine implants to treatment with 8 mg or less of an approved daily dosed sublingual formulation of buprenorphine.

12 Initial market research indicates that physicians would recommend Probuphine across wide patient population • Patients stabilized on buprenorphine therapy – Serious and committed patients with good treatment history • Patients that have a high relapse history – Patients with treatment compliance problems • New patients – Patients seeking discrete treatment or living in remote areas • Young patients (18 - 25 yrs ) – Needing long term maintenance, active lifestyle • Incarcerated patients – short term – Means of controlling incarceration - induced withdrawal Target Patient Profile

13 Efficacy Effective in reducing illicit opioid use Enhanced compliance may lead to superior outcomes Safety Lower drug exposure may provide superior safety and tolerability Ease of Use Unique delivery system dosed once every six months Continuous buprenorphine delivery • Non - fluctuating blood levels, around the clock medication • Potential 100% compliance Diversion Limited access to implants • Subdermal placement • Specific distribution (non - retail) Probuphine Value Proposition Probuphine is the first and only potential treatment for opioid dependence that can provide continuous and persistent around the clock blood levels of buprenorphine for six months, enhancing patient compliance and retention and preventing diversion

14 • Buprenorphine has several advantages over other opioids used for chronic pain • Safer than other opioids – Ceiling effect for respiratory depression, relatively long half - life, minimal euphoric effect • Buprenorphine transdermal patch (3 - 7 days) is approved in U.S., Europe and Australia for the treatment of moderate to severe chronic pain • Therapeutic window of 0.1 – 0.5 ng/ml plasma level can be delivered with 1 to 2 Probuphine implants • Probuphine value proposition for treating chronic pain • Around the clock non - fluctuating therapeutic levels, no on/off therapy cycling, enhances compliance and increases patient convenience • Braeburn Pharmaceuticals holds the U.S. and Canadian rights to the chronic pain indication Sources: NEJM 2003;349:1943 - 53 Sittl , Expert Rev. Neurotherapeutics 2005;5(3): 315 - 323 Potential for the Treatment of Chronic Pain

15 Titan: Adding Value Beyond Probuphine Proprietary ProNeura Technology Platform • Novel long - term drug delivery technology providing around - the - clock medication over periods of six months to a year clinically validated through the Probuphine program • Applicable to other chronic treatments where clinical benefit is possible through: – Low dose around the clock drug administration – Stable blood level of medication – Subdermal drug delivery eliminating first - pass metabolic effects • Product development program in Parkinson’s disease in progress – Established non - clinical proof of concept with continuous dopamine agonist treatment in a PD model with funding from NIH grants • Evaluation of additional compounds in other disease settings underway • Titan has an expert team in place with an established product development track record

16 Parkinson’s Disease Overview Parkinson’s Disease • Parkinson’s disease (PD) is characterized by the loss of dopaminergic neurons which leads to increasing activity in the brain region which influences movement and motor function Treatment • Early - stage PD patients are treated with drugs designed to replace dopamine in the brain. However, these therapeutics typically lose their benefits after several years of chronic treatment, and trigger serious side effects • About one third of the treated patients develop motor response fluctuations and/or drug - induced dyskinesias within only 2 years of treatment, increasing to over 50% within 3 - 5 years of treatment Research • Clinical and nonclinical research indicates that these motor side effects arise from the pulsatile dopaminergic stimulation resulting from current oral treatment modalities • Continuous dopaminergic stimulation (CDS) by subcutaneous infusion has been shown to palliate these motor complications and to also delay or prevent the onset of dyskinesias . Product Opportunity • Titan’s ProNeura ™ drug delivery technology provides a clinically - validated platform to safely and conveniently provide CDS for several months from a single treatment. Further, the subdermal placement of these implants eliminates many of the device - related complications associated with existing treatment modalities . .

17 Parkinson’s Disease: Treated Population Increasing Worldwide 17 Based on information from Titan and other sources believed to be reliable and prepared exclusively for Titan. Woodside Capita l P artners is not responsible for any use that Titan may make of this material.

18 Parkinson’s Disease: Therapeutics Market Source: GlobalData Sales for PD in the US by Drug Class 2012 – 2022 Year Total PD Sales % DA $ DA 2012 $1.1 bn 26% 286m 2022 $2.3bn 18% 414m About 1.5 million people in the U.S. have Parkinson’s disease according to the Parkinson’s Disease Foundation. The number is expected to double by 2030 because of the aging population. Sales of Dopamine Agonists, US Based on information from Titan and other sources believed to be reliable and prepared exclusively for Titan. Woodside Capita l P artners is not responsible for any use that Titan may make of this material.

19 ProNeura – Parkinson’s Disease Program • Non - clinical Proof of Concept • E valuation of ProNeura technology in MPTP Parkinsonian monkey model • Ropinirole (Requip ® ), a dopamine agonist marketed by GSK in the US for PD, was safely and continuously delivered from ProNeura - ropinirole implants inserted subdermally • No local skin irritation at implant site • Sustained non - fluctuating plasma ropinirole level for several months following implantation • C ontrolled PD symptoms without triggering dyskinesias in severely lesioned primates • Next Steps • Optimize implant formulation of ropinirole ; develop non - clinical study plan to support Investigational New Drug (IND) application • Design POC clinical study with assistance of the Scientific Advisory Board • P re - IND meeting with the FDA • Complete non - clinical studies to enable IND filing in late 2015 • P repare for conducting clinical study

20 Titan Pharmaceuticals is a specialty pharmaceutical company focused on developing innovative treatments for chronic conditions based on its proprietary long - term drug delivery platform, ProNeura™ • Probuphine, a long - acting controlled - release buprenorphine product for opioid dependence • Growing $1.5 billion market in opioid dependence; potential in chronic pain • $ 300 - $500M in potential annual peak sales in opioid dependence alone • A ddresses significant unmet needs : reduction in opioid use, increased compliance, avoidance of diversion and abuse • Attractive U.S. partnership: upfront $ 15.75M (12/12); approval, $15M; sales milestones, $ 165M; tiered royalties in mid - teens to low - twenties • NDA submission in late 2015 • ProNeura for Parkinson’s (ROPINIROLE) • Dopamine Agonist; continuous long term delivery in convenient outpatient setting • P otential to reduce motor fluctuations, dyskinesias and increase ‘on’ time • Expected IND filing in 2015; p roof - of - principle clinical study in 2016 • Proprietary ProNeura long - term drug delivery platform • Around - the - clock medications over six months to a year • Broad base of potential applications in chronic treatments Titan Pharmaceuticals Summary

21 Marc Rubin, M.D. July 30, 2008